Literature DB >> 1415534

Importance of basal glucagon in maintaining hepatic glucose production during a prolonged fast in conscious dogs.

G K Hendrick1, D H Wasserman, R T Frizzell, P E Williams, D B Lacy, J B Jaspan, A D Cherrington.   

Abstract

We undertook studies in conscious dogs to assess the role of basal glucagon in stimulating glucose production after a 7-day fast. Two protocols consisting of a 40-min basal period (-40 to 0 min), and a 180-min test period (0-180 min) were used. During the test period of the first protocol (hormone replacement; n = 4), somatostatin was infused (0.8 micrograms.kg-1.min-1) along with basal intraportal replacement amounts of insulin and glucagon, whereas in the second protocol (glucagon deficiency; n = 5), somatostatin plus insulin alone were infused. Glucose production and gluconeogenesis were measured using tracer and arteriovenous difference techniques. Plasma insulin levels were similar during the test period in both protocols (6 +/- 1 microU/ml). The plasma immunoreactive glucagon level in the control protocol averaged 50 +/- 8 pg/ml, whereas in the glucagon-deficiency protocol the level fell from 50 +/- 8 to 29 +/- 8 pg/ml (P less than 0.05). The plasma glucose level and the rate of glucose production were unchanged during bihormonal replacement. During glucagon deficiency the plasma glucose level was held constant at 100 +/- 4 mg/dl by glucose infusion. Tracer-determined endogenous glucose production fell from 1.8 +/- 0.1 to 1.0 +/- 0.1 mg.kg-1.min-1 by 30 min (P less than 0.05). After 3 h of glucagon deficiency, gluconeogenic conversion of alanine to glucagon was reduced 40% and the hepatic fractional extraction of alanine was reduced by 45%. The efficiency of the gluconeogenic process within the liver was not altered by glucagon deficiency.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415534     DOI: 10.1152/ajpendo.1992.263.3.E541

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  3 in total

1.  Dose-response effects of insulin glargine in type 2 diabetes.

Authors:  Zhihui Wang; Maka S Hedrington; Nino Gogitidze Joy; Vanessa J Briscoe; M Antoinette Richardson; Lisa Younk; Wendell Nicholson; Donna B Tate; Stephen N Davis
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

2.  Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects.

Authors:  N Paquot; P Schneiter; E Jéquier; R Gaillard; P J Lefèbvre; A Scheen; L Tappy
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

3.  Serum spexin concentration, body condition score and markers of obesity in dogs.

Authors:  Pawel Antoni Kolodziejski; Ewa Pruszynska-Oszmalek; Tomasz Nowak; Anna Lukomska; Maciej Sassek; Jan Wlodarek; Leszek Nogowski; Adam Cieslak; Krzysztof W Nowak
Journal:  J Vet Intern Med       Date:  2021-01-11       Impact factor: 3.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.